Evidence Snapshot
What this grade covers
C- reflects preclinical/mouse-model mechanistic evidence; human therapeutic efficacy evidence remains grade E (not established).
Regulatory Context
Not FDA-approved; investigational research peptide studied only in preclinical/animal models of hair regrowth.
Research Takeaway
PTD-DBM disrupts the CXXC5-Dishevelled interaction to activate Wnt/beta-catenin signaling, and preclinical mouse studies report hair-regrowth and wound-induced hair-neogenesis effects from this mechanism.
Evidence boundary: Preclinical mouse-model findings do not establish human hair-regrowth efficacy.
See all 2 evidence claims →Quick Summary
PTD-DBM is a protein-transduction-domain-linked Dishevelled-binding-motif competitor peptide designed to disrupt the CXXC5-Dishevelled interaction and modulate Wnt/beta-catenin signaling. Preclinical mouse studies report hair-regeneration effects, including stimulation of hair regrowth and wound-induced hair neogenesis (PMID 28595998) and a role for CXXC5 in DHT/PGD2-driven androgenetic alopecia (PMID 36831222); a 2025 review situates this within the broader Wnt/beta-catenin hair-follicle-neogenesis literature (PMID 40497955). These are preclinical mouse-model findings, not evidence of human efficacy, and DHT/PGD2 androgenetic-alopecia models do not by themselves establish a treatment effect in people. Wnt-pathway activation is not universally beneficial and carries theoretical pathway-risk considerations that preclinical hair-focused studies do not address. No adequate human randomized therapeutic trial was identified, and no injectable or systemic dosing can be inferred from this topical/preclinical work.
Mechanism & Research Overview
PTD-DBM is a protein-transduction-domain-linked Dishevelled-binding-motif competitor peptide designed to disrupt the CXXC5-Dishevelled interaction and modulate Wnt/beta-catenin signaling. Preclinical mouse studies report hair-regeneration effects, including stimulation of hair regrowth and wound-induced hair neogenesis (PMID 28595998) and a role for CXXC5 in DHT/PGD2-driven androgenetic alopecia (PMID 36831222); a 2025 review situates this within the broader Wnt/beta-catenin hair-follicle-neogenesis literature (PMID 40497955). These are preclinical mouse-model findings, not evidence of human efficacy, and DHT/PGD2 androgenetic-alopecia models do not by themselves establish a treatment effect in people. Wnt-pathway activation is not universally beneficial and carries theoretical pathway-risk considerations that preclinical hair-focused studies do not address. No adequate human randomized therapeutic trial was identified, and no injectable or systemic dosing can be inferred from this topical/preclinical work.
Evidence Claims
Individual scientific statements drawn from the sources cited below, each shown with the specific evidence boundary that statement does not establish.
Supported
PTD-DBM disrupts the CXXC5-Dishevelled interaction to activate Wnt/beta-catenin signaling, and preclinical mouse studies report hair-regrowth and wound-induced hair-neogenesis effects from this mechanism.
Does not establish
Evidence boundary: Preclinical mouse-model findings do not establish human hair-regrowth efficacy.
Supported
Wnt/beta-catenin pathway activation is not universally beneficial; preclinical hair-focused studies of PTD-DBM do not address broader pathway-risk considerations, and no adequate human randomized therapeutic trial exists.
Safety & Evidence Limitations
Considerations reported in the sources cited on this page — not a complete list of every possible risk, and not medical advice.
Research Areas Being Studied
Research areas discussed on this page reflect the Dermatology / Cosmetic Research category and the sources cited below.
Findings Reported in Studies
Educational summary only — reported in cited studies, not a claim of proven benefit.
No Human Study Findings Listed Yet
See preclinical, regulatory, and review sources below.
Study Tables by Evidence Type
No Sources Listed Yet
Human, preclinical, regulatory, and review sources will appear here as they are added.
Anecdotal Reported Patterns — Not Medical Advice
Anecdotal Reported Patterns — Not Medical Advice
Reported dosing patterns are included for educational context only. They are self-reported, unverified, not medical advice, and not instructions for human use. Community-submitted patterns are not yet available in this Phase 1 prototype; this section is a placeholder reserved for moderated, aggregated community data.
Lab Markers to Discuss With a Clinician
Educational topics only — not self-monitoring instructions.
FAQ
Disclaimer
Educational use only. This content is provided for informational and research-summary purposes only. It is not medical advice, not a treatment recommendation, not a dosing guide, and not a substitute for care from a licensed medical professional. Nothing here is intended to diagnose, treat, cure, prevent, or mitigate disease. Reported dosing patterns, when shown elsewhere on the site, must be labeled either as Study / Trial Dosing or Anecdotal Reported Patterns — Not Medical Advice. Community reports are self-reported, unverified, and not scientific proof.
Community-reported experiences, once enabled, must be displayed only as moderated, anonymized, or aggregated data. They are anecdotal, self-reported, unverified, and should never be presented as proof of safety, efficacy, or expected results.
Content status: Published. Last updated .
Follow research updates for PTD-DBM
Get notified in your MitoCore account when this profile is updated, a new study is added, or its evidence grade changes.
Get updates when new studies or safety notes are added for this peptide.
Get educational updates on new studies, evidence-grade changes, and safety notes. Educational content only — not medical advice.